drugset / Trial / NCT07053436
Horizon Two: HR NDMM (MMRC-100)
RandomizedParallel-groupOpen-labelTreatment
Summary
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2035-10-01
- Completion
- 2035-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Isatuximab | Monoclonal antibody | — | — |
| Subject | Linvoseltamab | Monoclonal antibody | — | — |
Indications
No indication recorded.